Wang JY, Lu YH, Li F, Huang ML. Pyroptosis: A promising biomarker for predicting colorectal cancer prognosis and enhancing immunotherapy efficacy. World J Clin Oncol 2024; 15(8): 968-974 [PMID: 39193165 DOI: 10.5306/wjco.v15.i8.968]
Corresponding Author of This Article
Mo-Li Huang, PhD, Professor, School of Biology and Basic Medical Sciences, Medical College of Soochow University, No. 199 Renai Road, Suzhou 215123, Jiangsu Province, China. huangml@suda.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 24, 2024; 15(8): 968-974 Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.968
Pyroptosis: A promising biomarker for predicting colorectal cancer prognosis and enhancing immunotherapy efficacy
Jia-Yi Wang, Yu-Hao Lu, Fang Li, Mo-Li Huang
Jia-Yi Wang, Yu-Hao Lu, Fang Li, Mo-Li Huang, School of Biology and Basic Medical Sciences, Medical College of Soochow University, Suzhou 215123, Jiangsu Province, China
Author contributions: Wang JY and Lu YH contributed to manuscript writing; Huang ML designed the overall concept and outline of the manuscript; Li F and Huang ML contributed to manuscript revision; all authors approved the final manuscript.
Supported byNational Natural Science Foundation of China, No. 32370598 and No. 31971117.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mo-Li Huang, PhD, Professor, School of Biology and Basic Medical Sciences, Medical College of Soochow University, No. 199 Renai Road, Suzhou 215123, Jiangsu Province, China. huangml@suda.edu.cn
Received: March 14, 2024 Revised: May 24, 2024 Accepted: July 2, 2024 Published online: August 24, 2024 Processing time: 155 Days and 4.8 Hours
Abstract
In this editorial, we comment on the article by Zhu et al published in the recent issue of the World Journal of Clinical Oncology. We focus specifically on the characteristics and mechanisms of pyroptosis and the impact of changes in the tumor immune microenvironment (TIME) on cancer prognosis. Pyroptosis is a distinct form of programmed cell death; its occurrence can change the TIME and regulate the growth and spread of tumors and therefore is significantly correlated with cancer prognosis. Previous research has demonstrated that pyroptosis-related genes can be used in prognostic models for various types of cancer. These models enhance the mechanistic understanding of tumor evolution and serve as valuable guides for clinical treatment decision-making. Nevertheless, further studies are required to thoroughly understand the function of pyroptosis within the TIME and to assess its mode of action. Such studies should reveal new tumor therapeutic targets and more successful tumor immunotherapy strategies.
Core Tip: Pyroptosis plays a vital role in tumor immunotherapy by triggering robust inflammatory responses and significantly inhibiting tumors. Pyroptosis results in the release of copious amounts of inflammatory cytokines and tumor-associated antigens that stimulate antigen-presenting cells, thereby initiating adaptive immune responses. Therefore, inducing pyroptosis is a promising novel immunotherapy approach for tumors.
